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tration and monitoring were estimated by an expert panel survey
conducted among 10 rheumatologists. Both health beneﬁts and
future costs were discounted at annual rate of 3%. One-way
sensitivity analyses were performed on key model parameters by
varying the input values by 10%. RESULTS: Compared to
current treatment arm, adding RTX yielded an incremental cost-
effectiveness ratio (ICER) of USD$18,152 (NTD$589,945) per
QALY gained. RTX remained cost-effective under one-way sen-
sitivity testing. Furthermore, applying RTX right after ETAN
or ADAL inadequate response (IR) rather than switching
between these two TNF inhibitors resulted in signiﬁcant cost-
savings of USD$14,922 (NTD$484,994) and USD$19,707
(NTD$640,481) respectively. CONCLUSION: From Taiwan
BNHI perspective, this demonstrates that adding RTX to current
treatment options for RA patients who respond inadequately to
TNF inhibitor therapy is cost-effective, in addition, applying
RTX right after one TNF inhibitor (ETAN or ADAL) IR is
cost-saving.
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OBJECTIVE: To assess cost-effectiveness of zoledronic acid
compared to risedronate in the Brazilian private health care
system, by health plan companies’ perspective. METHODS:
Decision analytic model (Markov) to estimate the incremental
cost effectiveness ratio of zoledronic acid compared to risedr-
onate for the treatment of osteoporosis in Brazil in 2007. The
target population was a hypothetic cohort of women with
osteoporosis aged 65 years in a time horizon of 5 years. The
epidemiological data related to osteoporosis and drug’s efﬁcacy
were obtained from critical appraisal of scientiﬁc literature. The
costs were collected from electronic claims databases of
patients enrolled in Brazilian health plans. The outcome ana-
lyzed was the cost per osteoporotic hip fracture avoided. Costs
and clinical beneﬁts related to the treatment were discounted at
a rate of 3%. RESULTS: In the base case scenario, zoledronic
acid reduced the incidence of fractures in comparison to risedr-
onate (0.33 fractures against 0.46 fractures), with similar
annual costs of osteoporosis treatment and its complications in
both arms of the model (US$10,607.35 against US$10,606.22,
incremental costs of US$1.13). CONCLUSION: The study
demonstrated that the use of zoledronic acid compared to
risedronate could prevent more hip fractures, with similar costs
in the brazilian private health system. This study highlights the
savings to health plan companies if an osteoporotic hip fracture
can be avoided.
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OBJECTIVE: To consolidate the cost-effectiveness (CE) data of
biologics in Rheumathoid Arthritis (RA) and explore their local
applicability. METHODS: Systematic review of CE studies (e.g.,
electronic databases searched to Nov. 2007) comparing biologics
with conventional DMARDs for RA patients. Details regarding
study characteristicswere abstracted using a framework byDrum-
mond et al. 2005 and study quality via Neuman et al. 2000 (score
1–7 higher better). ICER data was extracted, purchasing-power-
parity converted and pro-rated to 2006 Canadian $. RESULTS:
Nineteen CUA and 2 CEA studies published in 2002–2007
(UK = 7 studies, US 5, Canada = 3, Sweden = 4, Netherlands/
Japan = 1 each; ETA = 10, INF = 8, ADA = 2, ANA = 1; payer
perspective = 11, societal = 7 and not reported = 3 were identiﬁed
via screening 337 citations and reviewing 50 full-text articles.
Study methods varied (e.g., input efﬁcacy data, time horizon,
offset costs) but reporting quality was high (17/21). 20/21 study
populations involved RA patients refractory to one or more
DMARDs. The direct cost per QALY was $127–174 K for ETA
third line in Canada (n = 2 studies), $60–104 K mid-sequence in
the UK (n = 2), $60–176 K in Sweden (n = 3), and $256–483 K in
The Netherlands (n = 1). For INF with methotrexate, the cost per
QALY was $99–114 K in Canada (n = 1) and $62–289 K in the
UK (n = 2). It was $62–293 K for ADA (n = 1) and $233–1290 K
for ANA (n = 1). Other results from industry-funded studies
varied (n = 7). Antibodies against TNF was showed to be cost
effective at $50 K per QALY using data from the UK Rheumatol-
ogy Biologics Registry (n = 1). Two sources of uncertainty
frequently identiﬁed in sensitivity analyses: long-term disease
progression (10/17) and associated QALY (7/17). CONCLU-
SION: For direct cost, the relative cost effectiveness of the biolog-
ics is consistent with their relative clinical effectiveness, especially
the estimates of HAQ progression while on treatment.
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OBJECTIVE: To investigate the cost-effectiveness of biological
response modiﬁers in patients with moderate to severe rheuma-
toid arthritis who have experienced an inadequate response to
methotrexate METHODS: A decision analytic model was con-
structed to estimate the costs and effectiveness of adalimumab,
anakinra, etanercept, and inﬂiximab alone or in combination
with methotrexate for 6 months. Effectiveness was measured by
American College of Rheumatology response criteria (ACR20) as
reported in published clinical trials. Costs included direct medical
costs (including medication, monitoring, and adverse event costs)
and indirect costs due to impaired work productivity. Extensive
univariate and probabilistic sensitivity analyses were performed.
RESULTS: In the base case, costs for 6 months of therapy were
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